Video
Dr. Siefker-Radtke discusses current research on the use of erdafitinib to treat urothelial carcinoma
Author(s):
"In a phase 2 clinical trial, we saw that erdafitinib had an objective response rate of around 40% in patients who received prior chemotherapy for their metastatic disease," says Dr. Siefker-Radtke.
Video Player is loading.
Arlene O. Siefker-Radtke, MD, is a professor of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston. In this interview, Siefker-Radtke discusses the ongoing trials on the use of erdafitinib to treat FGFR3 altered urethelial cancers. She was interviewed during the 2022 LUGPA Annual Meeting in Chicago, Illinois.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Related Videos
Jad Chahoud, MD, on the phase 1b STELLAR-002 trial in ccRCC
Jens Bedke, MD, on efficacy of EV plus pembrolizumab across subgroups in la/mUC
Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
5 key trial insights from AUA 2025
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Related Content
